Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hillchol (BBV131) Phase III Non-inferiority Study
NCT05732766Phase 3Unknown
- Sponsor
- Bharat Biotech
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Hillchol in cholera (2 arms), sponsored by Bharat Biotech. Primary endpoints: Immediate adverse event reaction, Solicited adverse events at 7 days and 4 more. Status: unknown.
02
Drugs
Hillchol
03
Conditions
cholera
Beyond the preview
Go deeper on NCT05732766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732766.